User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference.

Primary tabs

download
  • Open access
  • PDF
  • 511.70 K
Yiannakou, Yan Tack, Jan Piessevaux, Hubert [UCL] Dubois, Dominique Quigley, Eamonn Kerstens, René

Background: The Patient Assessment of Constipation-Symptoms (PAC-SYM) questionnaire is frequently used in clinical trials of constipation. However, the threshold for reduction in total PAC-SYM score used to define a clinical response on this 0-4 point scale has not undergone formal appraisal, and its relationship with clinical benefit as perceived by patients has not been defined. Aim: To determine the minimal important difference in PAC-SYM score, and the optimum cut-off value for defining responders. Methods: The minimal important difference was estimated using data from six international phase 3/4, double-blind, randomised controlled trials of prucalopride in patients with chronic constipation (NCT01147926, NCT01424228, NCT01116206, NCT00485940, NCT00483886, NCT00488137), with anchor- and distribution-based approaches. Five appropriate patient-reported outcomes were selected as anchors. In addition, receiver operating characteristics (ROC) curve analyses were used to investigate responder discrimination for each anchor. Results: Data from 2884 patients were included. Minimal important difference estimates ranged from –0.52 to –0.63 across the five anchors. Estimates were not affected by study location but were consistently lower for rectal symptoms than for abdominal and stool symptoms. Distribution-based estimates were considerably lower than anchor-based estimates. ROC curve analyses showed optimum cut-off scores for discriminating responders to be similar to anchor-based minimal important difference estimates. Conclusions: Anchor-based methods gave consistent results for the minimal important difference, at approximately –0.6, and this value was close to the ROC-determined optimal cut-off scores for responder discrimination. This value could be considered in clinical practice. A slightly more conservative threshold (eg –0.75) could be used in clinical trials to reduce the placebo response rate

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2017
Language Anglais
Journal information "Alimentary Pharmacology and Therapeutics" - Vol. 46, no.11-12, p. 1103-1111 (2017)
Peer reviewed yes
Publisher Wiley-Blackwell Publishing Ltd. ((United Kingdom) Oxford)
issn 0269-2813
e-issn 1365-2036
Publication status Publié
Affiliations UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service d'hépato-gastro-entérologie
Links
  1. Belsey, Aliment Pharmacol Ther, 31, 938 (2010)
  2. L. Frank, L. Kleinman, C. Farup, L., Psychometric Validation of a Constipation Symptom Assessment Questionnaire, 10.1080/003655299750025327
  3. Johanson John F., Wald Arnold, Tougas Gervais, Chey William D., Novick James S., Lembo Anthony J., Fordham Fiona, Guella Mary, Nault Brigitte, Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trial, 10.1016/s1542-3565(04)00356-8
  4. Lin San-Ren, A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation, 10.3748/wjg.v13.i5.732
  5. Mihaylov S, Stark C, McColl E, Steen N, Vanoli A, Rubin G, Curless R, Barton R, Bond J, Stepped treatment of older adults on laxatives. The STOOL trial, 10.3310/hta12130
  6. Barish Charles F., Drossman Douglas, Johanson John F., Ueno Ryuji, Efficacy and Safety of Lubiprostone in Patients with Chronic Constipation, 10.1007/s10620-009-1068-x
  7. Ahmedzai Sam H., Leppert Wojciech, Janecki Marcin, Pakosz Artur, Lomax Mark, Duerr Heike, Hopp Michael, Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain, 10.1007/s00520-014-2435-5
  8. Sakai T., Kubota H., Gawad A., Gheyle L., Ramael S., Oishi K., Effect of fermented milk containingLactobacillus caseistrain Shirota on constipation-related symptoms and haemorrhoids in women during puerperium, 10.3920/bm2014.0076
  9. Marciniak Christina M, Toledo Santiago, Lee Jungwha, Jesselson Michael, Bateman Jillian, Grover Benjamin, Tierny Joy, Lubiprostonevs Sennain postoperative orthopedic surgery patients with opioid-induced constipation: A double-blind, active-comparator trial, 10.3748/wjg.v20.i43.16323
  10. Huang Tzu-Ting, Yang Shu-Di, Tsai Yu-Hsia, Chin Yen-Fan, Wang Bi-Hwa, Tsay Pei-Kwei, Effectiveness of individualised intervention on older residents with constipation in nursing home: a randomised controlled trial, 10.1111/jocn.12974
  11. Yiannakou Yan, Piessevaux Hubert, Bouchoucha Michel, Schiefke Ingolf, Filip Rafal, Gabalec Libor, Dina Ion, Stephenson David, Kerstens René, Etherson Kevin, Levine Amy, A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of Prucalopride in Men With Chronic Constipation, 10.1038/ajg.2015.115
  12. Thomas G. P., Duelund-Jakobsen J., Dudding T. C., Bradshaw E., Nicholls R. J., Alam A., Emmanuel A., Thin N., Knowles C. H., Laurberg S., Vaizey C. J., A double-blinded randomized multicentre study to investigate the effect of changes in stimulation parameters on sacral nerve stimulation for constipation, 10.1111/codi.12982
  13. Sloots Cornelius E. J., Rykx An, Cools Marina, Kerstens Rene, De Pauw Martine, Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation, 10.1007/s10620-010-1229-y
  14. Slappendel Robert, Simpson Karen, Dubois Dominique, Keininger Dorothy L., Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain, 10.1016/j.ejpain.2005.03.008
  15. O'Brien Catherine E, Anderson Paula J, Stowe Cindy D, Lubiprostone for Constipation in Adults with Cystic Fibrosis: A Pilot Study, 10.1345/aph.1q219
  16. Müller-lissner S., Rykx A., Kerstens R., Vandeplassche L., A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation : Prucalopride in elderly constipated patients, 10.1111/j.1365-2982.2010.01533.x
  17. Iyer Shrividya S., Randazzo Bruce P., Tzanis Evan L., Schulman Seth L., Zhang Haiying, Wang Wenjin, Manley Amy L., Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms, 10.1016/j.jval.2010.11.003
  18. Iqbal F., Collins B., Thomas G. P., Askari A., Tan E., Nicholls R. J., Vaizey C. J., Bilateral transcutaneous tibial nerve stimulation for chronic constipation, 10.1111/codi.13105
  19. Speed C, Heaven B, Adamson A, Bond J, Corbett S, Lake AA, May C, Vanoli A, McMeekin P, Moynihan P, Rubin G, Steen IN, McColl E, LIFELAX – diet and LIFEstyle versus LAXatives in the management of chronic constipation in older people: randomised controlled trial, 10.3310/hta14520
  20. Khan U., Mason J. M., Mecci M., Yiannakou Y., A prospective trial of temporary sacral nerve stimulation for constipation associated with neurological disease, 10.1111/codi.12789
  21. Camilleri Michael, Piessevaux Hubert, Yiannakou Yan, Tack Jan, Kerstens René, Quigley Eamonn M. M., Ke MeiYun, Da Silva Susana, Levine Amy, Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials, 10.1007/s10620-016-4147-9
  22. Jaeschke Roman, Singer Joel, Guyatt Gordon H., Measurement of health status, 10.1016/0197-2456(89)90005-6
  23. Camilleri Michael, Kerstens René, Rykx An, Vandeplassche Lieve, A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation, 10.1056/nejmoa0800670
  24. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L, Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives, 10.1136/gut.2008.162404
  25. QUIGLEY E. M. M., VANDEPLASSCHE L., KERSTENS R., AUSMA J., Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study, 10.1111/j.1365-2036.2008.03884.x
  26. Ke M., Zou D., Yuan Y., Li Y., Lin L., Hao J., Hou X., Kim H. J., Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study : Prucalopride treatment for chronic constipation, 10.1111/j.1365-2982.2012.01983.x
  27. Piessevaux H., Corazziari E., Rey E., Simren M., Wiechowska-Kozlowska A., Kerstens R., Cools M., Barrett K., Levine A., A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride, 10.1111/nmo.12553
  28. Revicki Dennis, Hays Ron D., Cella David, Sloan Jeff, Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes, 10.1016/j.jclinepi.2007.03.012
  29. Beaton Dorcas E., Boers Marteen, Wells George A., Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research : , 10.1097/00002281-200203000-00006
  30. Guyatt Gordon H., Osoba David, Wu Albert W., Wyrwich Kathleen W., Norman Geoffrey R., Methods to Explain the Clinical Significance of Health Status Measures, 10.4065/77.4.371
  31. Zweig, Clin Chem, 39, 561 (1993)
  32. Hays, Assessing quality of life in clinical trials, 25 (2005)
  33. Wells, J Rheumatol, 28, 406 (2001)
  34. Copay Anne G., Subach Brian R., Glassman Steven D., Polly David W., Schuler Thomas C., Understanding the minimum clinically important difference: a review of concepts and methods, 10.1016/j.spinee.2007.01.008
  35. Kaptchuk Ted J., Friedlander Elizabeth, Kelley John M., Sanchez M. Norma, Kokkotou Efi, Singer Joyce P., Kowalczykowski Magda, Miller Franklin G., Kirsch Irving, Lembo Anthony J., Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome, 10.1371/journal.pone.0015591
  36. Neri Luca, , Conway Paul Maurice, Basilisco Guido, Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation, 10.1007/s11136-014-0886-2
Bibliographic reference Yiannakou, Yan ; Tack, Jan ; Piessevaux, Hubert ; Dubois, Dominique ; Quigley, Eamonn ; et. al. The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference.. In: Alimentary Pharmacology and Therapeutics, Vol. 46, no.11-12, p. 1103-1111 (2017)
Permanent URL http://hdl.handle.net/2078.1/201196